|
|
|
|
|
by dekhn
2032 days ago
|
|
DeepMind is taking advantage of NIH's funding.
For example, Anfinsen who demonstrated that proteins fold spontaneously and reproducibly (https://en.wikipedia.org/wiki/Anfinsen%27s_dogma) ran a lab at NIH. Levinthal (who postulated an early and easily refutable model of protein folding) was funded by NIH for decades. Most of the competitors at CASP are supported by NIH and its investments have contributed to the modern results significantly. That said I think the academic and pharma communities had engineered themselves into a corner and weren't going to see huge gains (even thogh they are exploring similar ideas) for a number of banal reasons. |
|
What I meant to focus on was that I think DeepMind has less of a pure money/scale advantage in this area than in some others. In something like Go or Atari game-playing, there are many academic groups researching similar things, but their resources are laughably small compared to what DeepMind threw at it. So you might argue that they got good results there in part because they directed 1000x the personnel and compute at the problem compared to what any academic group could afford. In biomed though, their peers in academia and industry are also pretty well-funded.